AQST Aquestive Therapeutics, Inc.

NASDAQ
$3.78

Aquestive Therapeutics, Inc. (AQST) is expected to report earnings on February 2, 2027, after the market close. The consensus earnings estimate is a loss of $0.11 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +3.3% since its last earnings release on November 3, 2026.

Aquestive Therapeutics Missed Consensus Estimates, Reaffirms
Tuesday, November 3, 2026 · 4:01 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 2
Tuesday · 4:00 PM ET
Earnings Whisper
-
vs ($0.11)
Rev est $11.13M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $3.67

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Aquestive Therapeutics, Inc.

Aquestive Therapeutics is a pharmaceutical company that applies innovative technology to solve therapeutic problems and improve medicines for patients.

Sector

Healthcare

Industry

Drug Delivery

Charts powered in part by Lightweight Charts™ by TradingView.